Portland, OR, United States
Portland, OR, United States

Time filter

Source Type

Partnership facilitates therapeutic biomarker and target validation, assay development and clinical trial management for companion diagnostics and drug development PORTLAND, OR and CAMBRIDGE, MA and DETROIT, MI--(Marketwired - February 15, 2017) - Asterand Bioscience, the leader in high quality, well-characterized human tissue and human tissue-based research solutions supporting drug discovery and development, announced today a partnership with MolecularMD to combine MolecularMD's expertise as a provider of molecular diagnostics products and services with Asterand Bio's drug target and candidate validation capabilities. MolecularMD is a molecular diagnostics company that develops custom clinical trial assays as well as companion diagnostic products, supporting clinical trial services and commercialization of targeted cancer therapies. The partnership creates an end-to-end workflow for biopharma clients and strengthens the companies' current offerings in assay development & validation, while creating a global footprint for the efficient delivery of clinical trial sample analyses. "For over 20 years, Asterand Bioscience's experienced scientists have worked collaboratively with clients to expedite the highest likelihood for clinical success by providing a variety of pre-clinical research services," said John Canepa, Chief Financial Officer/Chief Operations Officer. "This agreement brings together MolecularMD's proven track record in clinical assay development and companion diagnostics with Asterand Bio's human tissue procurement, characterization and research services to provide a comprehensive approach to meet the needs of pharmaceutical, biotechnology and diagnostic companies from validation of biomarkers and targets to assay development, through regulatory and clinical trials." "MolecularMD is uniquely suited to assist biopharma clients with our clinical trial and regulatory expertise," said Dan Snyder, President/Chief Executive Officer, MolecularMD. "I'm excited that Asterand Bio and MolecularMD have joined forces to provide these unique advantages which will help our broad client base accelerate their pipeline decisions and dramatically improve the efficiency of the clinical trial and commercialization workflow." Asterand Bio and MolecularMD will both attend Molecular Med Tri-Con 2017, Feb 19-24 at the Moscone North Convention Center, San Francisco, CA, a meeting bringing together over 3,500 drug discovery and development professionals. More information about the partnership can be found at Asterand Bio's booth #626. Asterand Bio and MolecularMD will both attend the AACR 2017 meeting, April 1-5 at the Walter E. Washington Convention Center in Washington DC, a meeting that highlights the highest level of cancer science and medicine from institutions all over the world. More information about the partnership can be found at Asterand Bio's booth #1340 and MolecularMD's booth #3423. About Asterand Bioscience Asterand Bioscience is the leading global provider of high quality, well-characterized human tissue and human tissue-based research solutions to drug discovery scientists. Our mission is to provide human-based solutions to accelerate the identification and validation of drug targets and enhance the selection of drug candidates with increased likelihood of clinical success. From our offices in Detroit, MI and Royston, U.K. our employees are focused on providing services and products to accelerate drug discovery research from target identification through to compound evaluation and drug safety. About MolecularMD MolecularMD Corporation develops and commercializes specialty molecular diagnostics for oncology applications. Tests are designed to allow appropriate selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. MolecularMD integrates gold-standard and innovative platform technologies with clinical assay design, validation and centralized testing to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents.


PORTLAND, Ore. & CAMBRIDGE, Mass. & DETROIT--(BUSINESS WIRE)--Asterand Bioscience, the leader in high quality, well-characterized human tissue and human tissue-based research solutions supporting drug discovery and development, announced today a partnership with MolecularMD to combine MolecularMD’s expertise as a provider of molecular diagnostics products and services with Asterand Bio’s drug target and candidate validation capabilities. MolecularMD is a molecular diagnostics company that develops custom clinical trial assays as well as companion diagnostic products, supporting clinical trial services and commercialization of targeted cancer therapies. The partnership creates an end-to-end workflow for biopharma clients and strengthens the companies’ current offerings in assay development & validation, while creating a global footprint for the efficient delivery of clinical trial sample analyses. “For over 20 years, Asterand Bioscience’s experienced scientists have worked collaboratively with clients to expedite the highest likelihood for clinical success by providing a variety of pre-clinical research services,” said John Canepa, Chief Financial Officer/Chief Operations Officer. “This agreement brings together MolecularMD’s proven track record in clinical assay development and companion diagnostics with Asterand Bio’s human tissue procurement, characterization and research services to provide a comprehensive approach to meet the needs of pharmaceutical, biotechnology and diagnostic companies from validation of biomarkers and targets to assay development, through regulatory and clinical trials.” “MolecularMD is uniquely suited to assist biopharma clients with our clinical trial and regulatory expertise,” said Dan Snyder, President/Chief Executive Officer, MolecularMD. “I’m excited that Asterand Bio and MolecularMD have joined forces to provide these unique advantages which will help our broad client base accelerate their pipeline decisions and dramatically improve the efficiency of the clinical trial and commercialization workflow.” Asterand Bio and MolecularMD will both attend Molecular Med Tri-Con 2017, Feb 19-24 at the Moscone North Convention Center, San Francisco, CA, a meeting bringing together over 3,500 drug discovery and development professionals. More information about the partnership can be found at Asterand Bio’s booth #626. Asterand Bio and MolecularMD will both attend the AACR 2017 meeting, April 1-5 at the Walter E. Washington Convention Center in Washington DC, a meeting that highlights the highest level of cancer science and medicine from institutions all over the world. More information about the partnership can be found at Asterand Bio’s booth #1340 and MolecularMD’s booth #3423. Asterand Bioscience is the leading global provider of high quality, well-characterized human tissue and human tissue-based research solutions to drug discovery scientists. Our mission is to provide human-based solutions to accelerate the identification and validation of drug targets and enhance the selection of drug candidates with increased likelihood of clinical success. From our offices in Detroit, MI and Royston, U.K. our employees are focused on providing services and products to accelerate drug discovery research from target identification through to compound evaluation and drug safety. MolecularMD Corporation develops and commercializes specialty molecular diagnostics for oncology applications. Tests are designed to allow appropriate selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. MolecularMD integrates gold-standard and innovative platform technologies with clinical assay design, validation and centralized testing to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents.


PORTLAND, Oregon CAMBRIDGE, Massachusetts et DÉTROIT--(BUSINESS WIRE)--Asterand Bioscience, fournisseur leader de tissus humains bien caractérisés de haute qualité ainsi que de solutions de recherche à base de tissus humains en appui de la découverte et du développement de médicaments, a annoncé aujourd'hui avoir conclu avec MolecularMD un partenariat visant à combiner l'expertise de MolecularMD, en tant que fournisseur de produits et services de diagnostic moléculaire, avec les capacités de validation d'Asterand Bioscience en matière de produits candidats et de cibles médicamenteuses. MolecularMD est une société spécialisée dans le domaine des diagnostics moléculaires, qui développe des tests d'essais cliniques sur mesure ainsi que des produits diagnostics compagnons, en soutien de services d'essais cliniques et de la commercialisation de thérapies ciblées contre le cancer. Ce partenariat crée un flux de travail de bout en bout pour les clients biopharmaceutiques, et renforce l'offre actuelle des deux sociétés en matière de développement et de validation de tests, tout en établissant une présence mondiale permettant la délivrance efficace d'analyses d'échantillons d'essais cliniques. « Depuis plus de 20 ans, les scientifiques expérimentés d'Asterand Bioscience travaillent en étroite collaboration avec les clients de la société afin de faciliter les plus hautes probabilités de réussite clinique, en fournissant divers services de recherche préclinique, » a déclaré John Canepa, directeur financier/directeur d'exploitation. « Cet accord permet de combiner l'expérience reconnue de MolecularMD en matière de développement de tests cliniques et de diagnostics compagnons, avec les services d'approvisionnement, de caractérisation et de recherche d'Asterand Bio dans le domaine des tissus humains, afin de créer une approche globale permettant de répondre aux besoins des sociétés pharmaceutiques, biotechnologiques et de diagnostic, qu'il s'agisse de la validation de biomarqueurs et de cibles ou du développement de tests, tout au long des étapes réglementaires et des essais cliniques. » « MolecularMD est idéalement positionnée pour aider les clients biopharmaceutiques grâce à son expertise en matière d'essais cliniques et de réglementation », a confié pour sa part Dan Snyder, président et chef de la direction de MolecularMD. « Je suis ravi que les sociétés Asterand Bio et MolecularMD aient uni leurs forces afin de pouvoir proposer ces avantages uniques, qui aideront notre vaste clientèle à accélérer les décisions liées à son pipeline, ainsi qu'à améliorer considérablement l'efficacité de leur flux de travail en matière d'essais cliniques et de commercialisation. » Asterand Bio et MolecularMD assisteront toutes deux à l'événement Molecular Med Tri-Con 2017, qui aura lieu du 19 au 24 février au Moscone North Convention Center de San Francisco, en Californie, rassemblement qui réunira plus de 3 500 professionnels spécialisés dans la découverte et le développement de médicaments. Pour en savoir plus sur ce partenariat, rendez-vous sur le stand n°626 d'Asterand Bio. Asterand Bio et MolecularMD assisteront également toutes deux au rassemblement de l'AACR 2017, qui se tiendra du 1er au 5 avril au Walter E. Washington Convention Center de Washington DC, rencontre visant à mettre en lumière ce qui se fait de mieux en termes de science et de médecine du cancer dans des institutions du monde entier. Pour en savoir plus sur ce partenariat, rendez-vous sur le stand n°1340 d'Asterand Bio, et sur le stand n°3423 de MolecularMD. Asterand Bioscience est le premier fournisseur mondial de tissus humains bien caractérisés de haute qualité ainsi que de solutions de recherche à base de tissus humains, auprès des scientifiques spécialisés dans la découverte de médicaments. Nous avons pour mission de fournir des solutions basées sur l'homme propres à accélérer l'identification et la validation de cibles médicamenteuses et à améliorer la sélection de médicaments candidats présentant un plus grand potentiel de succès clinique. Depuis nos bureaux de Détroit dans le Michigan, et de Royston au Royaume-Uni, nos employés s'attachent à fournir des services et des produits propres à accélérer la recherche en découverte médicamenteuse, depuis l'identification des cibles jusqu'à l'évaluation des composés et la sécurité d'emploi des médicaments. MolecularMD Corporation développe et commercialise des diagnostics moléculaires spécialisés, destinés à des applications d'oncologie. Ces tests sont conçus pour permettre une sélection appropriée, ainsi que le suivi et la gestion des patients traités pour un cancer au moyen de thérapies moléculaires ciblées. MolecularMD intègre des technologies de plateforme innovantes et de premier ordre à une démarche de conception, de validation et de tests centralisés des essais cliniques afin d'accélérer toutes les phases du développement clinique, y compris l'approbation par la FDA et la commercialisation de tests diagnostics compagnons in vitro pour de nouveaux agents anticancéreux.


„Seit über 20 Jahren arbeiten erfahrene Wissenschaftler von Asterand Bioscience gemeinsam mit Kunden des Unternehmens daran, durch ein Angebot diverser präklinischer Forschungsdienstleistungen, die Ansätze mit den höchsten Aussichten auf klinischen Erfolg voranzutreiben” sagte John Canepa, Chief Financial Officer/Chief Operations Officer. „Mit diesem Vertrag werden die Leistungen von MolecularMD in der Assayentwicklung und Begleitdiagnostik und die Erfahrung von Asterand Bioscience in der Bereitstellung und Charakterisierung von menschlichem Gewebe sowie als Forschungsdienstleister zusammengeführt, um einen ganzheitlichen Ansatz zu verfolgen, mit dem den Anforderungen von Pharma-, Biotechnologie und Diagnostikunternehmen begegnet werden soll, von der Validierung von Biomarkern und Targets bis zur Assay-Entwicklung.” Asterand Bio und MolecularMD werden beide auf der Med Tri-Con 2017 vertreten sein, die vom 19.-24. Februar im Moscone North Convention Center im kalifornischen San Francisco stattfindet. Bei dieser Tagung werden mehr als 3500 Fachleute aus den Bereichen Entdeckung und Entwicklung von Wirkstoffen anwesend sein. Weiterführende Information zum Zusammenschluss ist am Stand Nr. 626 von Asterand Bio erhältlich. Asterand Bio sowie MolecularMD werden auch am vom 1.- 5. April stattfindenden Meeting der AACR des Jahres 2017 im Walter E. Washington Convention Center in Washington DC teilnehmen. Dieses Meeting präsentiert die Krebsforschung und -medizin diverser Institutionen aus aller Welt auf dem höchsten Stand. Weiterführende Information zum Zusammenschluss ist am Stand Nr. 1340 von Asterand Bio und dem Stand Nr.3423 von MolecularMD erhältlich.


News Article | November 23, 2016
Site: www.newsmaker.com.au

ReportsnReports.com adds “Global Next Generation Sequencing Market Research Report 2016” new report to its research database. The report spread across 125 pages with table and figures in it. Global Next Generation Sequencing Market Report is a professional and in-depth research report on the world's major regional market conditions of the Next Generation Sequencing industry, focusing on the main regions and the main countries (United States, Europe, Japan and China). The report introduces Next Generation Sequencing basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc. Insightful predictions for the Next Generation Sequencing market for the coming few years have also been included in the report. These predictions feature important inputs from leading industry experts and take into account every statistical detail regarding the Next Generation Sequencing market. Complete report on the Next Generation Sequencing Market Research Report spread across 125 pages, profiling 15 companies and supported with 125 tables and figures is now available at @ http://www.reportsnreports.com/contacts/discount.aspx?name=761348 . #Key Manufacturers profiled in this research are Illumina, Inc., Qiagen N.V., QuantuMDx Group, Quest Diagnostics, RainDance Technologies, Inc., Response Genetics, Inc., Roche, SeqLL, LLC, Sequenta, Inc., Mayo Medical Laboratories and Mayo Clinic, MolecularMD Corporation, Multiplicom NV, DNA Electronics Ltd., DNASTAR, Inc. and Innovations Exchange Pte Ltd (INEX) no less than 15 top producers. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. The report focuses on global major leading Next Generation Sequencing Industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Global Next Generation Sequencing Industry 2016 is a comprehensive, professional report delivering market research data that is relevant for new market entrants or established players. Key strategies of the companies operating in the market and their impact analysis have been included in the report. Furthermore, a business overview, revenue share, and SWOT analysis of the leading players in the Next Generation Sequencing market is available in the report. With the list of tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. 1 Industry Overview 2 Manufacturing Cost Structure Analysis of Next Generation Sequencing 3 Technical Data and Manufacturing Plants Analysis 4 Production Analysis of Next Generation Sequencing by Regions, Technology, and Applications 5 Sales and Revenue Analysis of Next Generation Sequencing by Regions 6 Analysis of Next Generation Sequencing Production, Supply, Sales and Market Status 2010-2016 7 Analysis of Next Generation Sequencing Industry Key Manufacturers 8 Price and Gross Margin Analysis 9 Marketing Trader or Distributor Analysis of Next Generation Sequencing 10 Development Trend of Next Generation Sequencing Industry 2016-2021 11 Industry Chain Suppliers of Next Generation Sequencing with Contact Information 12 New Project Investment Feasibility Analysis of Next Generation Sequencing 13 Conclusion of the Global Next Generation Sequencing Industry Report 2016 Some of the tables and figures provided in Global Next Generation Sequencing Market Report 2016 research report include: Table Global Capacity (Unit) of  Next Generation Sequencing by Types 2011-2016 Figure Global Capacity Market Share of  Next Generation Sequencing by Types in 2011 Figure Global Capacity Market Share of  Next Generation Sequencing by Types in 2015 Table Global Production (Unit) of  Next Generation Sequencing by Types 2011-2016 Figure Global Production Market Share of  Next Generation Sequencing by Types in 2011 Figure Global Production Market Share of  Next Generation Sequencing by Types in 2015 Table Global Revenue (M USD) of  Next Generation Sequencing by Types 2011-2016 Figure Global Revenue Market Share of  Next Generation Sequencing by Types in 2011 Figure Global Revenue Market Share of  Next Generation Sequencing by Types in 2015 Table Global and Major Manufacturers Capacity (Unit) of  Next Generation Sequencing 2011-2016 Table Global Capacity Market Share of  Next Generation Sequencing Major Manufacturers 2011-2016 Figure Global Capacity Market Share of  Next Generation Sequencing Major Manufacturers in 2011 Figure Global Capacity Market Share of  Next Generation Sequencing Major Manufacturers in 2015 Table Global and Major Manufacturers Production (Unit) of  Next Generation Sequencing 2011-2016 Table Global Production Market Share of  Next Generation Sequencing Major Manufacturers 2011-2016 Figure Global Production Market Share of  Next Generation Sequencing Major Manufacturers in 2011 Figure Global Production Market Share of  Next Generation Sequencing Major Manufacturers in 2015 Table Global and Major Manufacturers Revenue (M USD) of  Next Generation Sequencing 2011-2016 Connect us @ [email protected] with subject line “2016 Market Research Report on Global Next Generation Sequencing Industry “ and your contact details to purchase this report or get your questions answered. OR Call Us @ +1 888 391 5441. ReportsnReports.com is an online market research reports library of 500,000+ in,depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.


Companion Diagnostics (CDx) - your guide to developments, opportunities and revenues See what the future holds for companion diagnostics. Visiongain's brand new report gives you revenue predictions for the CDx market and its submarkets from 2015, helping you stay ahead. Our 197-page report provides 114 tables, charts, and graphs. Discover the growing trends of this industry. In particular, our new study lets you assess forecasted sales at overall world market, submarket and national level. You will see financial results, drivers and restraints, and revenue predictions. Besides revenue forecast to 2025, this report provides you with market shares, business outlooks, qualitative analyses (including SWOT and Porter's Fiver Forces Analysis), company profiles and commercial partnerships. Also, read the full transcript of two exclusive expert opinion interviews to inform you about prospects for investments and sales: To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com Discover sales predictions for the overall IVD and CDx market See how the CDx market is forecasted to perform compared to the rest of the IVD market up to 2025. This will give you insight into the market share of the CDx market and how its market share in the IVD market is set to change over the forecast period. See revenue forecasts for CDx submarkets from 2015 to 2025 Along with prediction of overall world market value to 2025, our report shows you revenue forecasting for the two submarkets at world level: • Theranostics • Other Companion Diagnostics The analysis helps you identify potential with individual revenue forecasts and find ways for your business to develop. Discover prospects for the leading nations and regions to 2025 The regional market reach for CDx products is expanding as regulatory bodies worldwide are mandating the approval of diagnostics simultaneously with therapies. You will discover individual revenue forecasts to 2025 for 13 leading national markets and the rest of the world (RoW): • US • Japan • Germany • France • UK • Italy • Spain • China • Brazil • Russia • India • South Korea • Mexico • Rest of the World The uptake of novel companion diagnostic platforms in the emerging economies will be a major driver of growth in this market. Leading companion diagnostics companies and potential for market growth Our new study predicts the world market for CDx will reach $3.32bn in 2015. The trend of pharmaceutical companies establishing partnerships and collaborations with companion diagnostic companies, in earlier drug development stages, continues to increase. Our research profiles leading companies, assessing their financial performance and products. You will see which technologies and organisations hold the greatest potential. See the profiles of 9 leading companies: • Roche Diagnostics (including Ventana Medical Systems) • Qiagen • Abbott Molecular • Agilent (Dako) • Myriad Genetics • bioMérieux • Siemens Healthcare • Thermo Fisher Scientific • Lab 21 In general, a company profile gives you the following information: • Historical and recent revenue figures- including the individual diagnostics business sector • Discussion of a company's pipeline • Assessment of recent developments - mergers and acquisitions (M&A), new products, collaborations, including alliances, companion diagnostics partnerships and joint ventures. What does the development pipeline look like in the CDx market? Our report examines the current biomarkers and CDx test products on the market and also explores the future prospects of the CDx market: • The current CDx diagnostic and pharmaceutical partnerships including the pipeline disease area • The market potential of companion diagnostics across leading disease indications • The competitive landscape of the CDx market. What is currently restraining further growth in the CDx market? Our report discusses issues and events affecting the industry and market from 2015, including these: • The evolving regulatory framework around CDx and LDTs • The vested interests of different stakeholders • The reimbursement of CDx tests • The opportunities of next-generation sequencing technologies To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com How The Companion Diagnostics (CDx) Market Forecast 2015-2025 report helps you: In summary, our new 197-page report gives you the following knowledge: • Revenue forecasts to 2025 for the world CDx market and 2 submarkets - Discover the industry's prospects, finding promising places for investment and revenues. • Revenue forecasts to 2025 for the leading 13 national markets - US, Japan, Germany, France, UK, Italy, Spain, Brazil, Russia, China, India, South Korea, Mexico and the Rest of the World • Assessment of 9 leading companies - hear about CDx products, pipeline developments, financial results and strategies • Review of R&D pipelines - investigate developmental trends and progress • Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and get advantages. • View opinions from our survey, seeing interviews with leading CDx experts. You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence. Information found nowhere else With our study you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the CDx market and leading diagnostic companies. You find data, trends and predictions. Please order our report now. To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100 20/20 Gene Systems Abbott Diagnostics Abbott Molecular Affymetrix Agilent (Dako) Almac Ambry Genetics Amgen Arca bipharma Arno Astellas Pharma AstraZeneca Asuragen Bayer Biogenex Laboratories, Inc. bioMérieux Biomonitor Boehringer Ingelheim Brain Resource Company Bristol-Myers Squibb CancerGuide Diagnostics Caprion Proteomics Caris Life Sciences Celera (acquired by Quest Diagnostics) Celgene Cepheid ChemGenex Pharmaceuticals Clarient Clinical Reference Laboratory Clovis CompanDx Crescendo Bioscience Curidium Medica Dako (Agilent) Deloitte DiagnoCure Dx assays DxS Eli Lilly Endocyte Exosome Diagnostics Ferring Flagship Biosciences FlowMetric Diagnostics Foundation Medical Foundation Medicine Genentech Genfit Genia Technologies Genmab GenMark Diagnostics Gilead Sciences GlaxoSmithKline GSK Hexie Health HistologiX Idera Illumina ImmunoGen Incyte InDex Pharmaceuticals IntegraGen Inverness Medical Innovations (now known as Alere) Invivoscribe Technologies Ipsen Ipsogen IQuum Janssen Pharmaceutical Kimball Genetics (a division of LabCorp) Kunlun Health Insurance Lab Corp Lab21 Laboratory for Personalized Molecular Medicine Leica Leica Biosystems Leica Micosystems Life Technologies Medicare MedImmune (AstraZeneca) Merck Merck Serono MolecularMD Monogram Biosciences Myriad Genetics Myriad RBM Nanosphere Nanostring NanoString Technologies NIH Novartis Oxford BioTherapeutics (earlier Oxford Genome Sciences) Pacific Diagnostics Clinical Laboratory (ResearchDx)  Pfizer PICC Health Insurance Ping An Insurance Group Prionics Progenika Biopharma Prometheus Protagen Protagen Diagnostics Qiagen Quintiles Quintiles Transnational Corporation Randox Pharma Services ResearchDx Resonance Health Resonance Health Analysis Services RiboMed Biotechnologies Roche Rule-Based Medicine Saladax Biomedical Siemens Siemens Healthcare Signal Genetics Sirius Genomics Skyline Diagnostics Solvay Innogenetics Sysmex Inostics Takeda's Millennium unit Target Discovery TcLand Expression TESARO Theranostics (NZ) Theranostics Health Thermo Fisher Thermo Fisher Scientific Third Wave Technologies (Hologic) TIB MolBiol Tocagen Tragara Pharmaceuticals Transgenomic TRICARE TrimGen Corporation Unilabs Ventana Medical Systems (a subsidiary of Roche) ViiV Healthcare Weisenthal Cancer Group Other Organisations Mentioned in This Report Cancer Research UK College of American Pathology (CAP) European Medicines Agency (EMA) Medical Research Council National Health Insurance (NHI) (South Korea) Northern Institute for Cancer Research ServizioSanitarioNazionale (SSN) Sistema Único de Saúde (SUS) The Association of British Pharmaceutical Industries The Food and Drug Administration (FDA) The Haute Autorité de santé (HAS) The National Institute for Health and Care Excellence (NICE) Tufts Center for the Study of Drug Development University of Newcastle To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com


PORTLAND, Ore. & CAMBRIDGE, Mass. & DETROIT--(BUSINESS WIRE)--Asterand Bioscience, proveedor líder de tejidos humanos bien caracterizados y de alta calidad, así como soluciones de investigación basada en tejidos humanos que ayudan al descubrimiento y desarrollo de fármacos, ha anunciado una alianza con MolecularMD para combinar la experiencia de ésta como proveedor de productos y servicios de diagnóstico molecular con las capacidades de validación de candidatos y objetivo de fármacos de Asteran


PORTLAND, Oregon, CAMBRIDGE, Massachusetts, e DETROIT--(BUSINESS WIRE)--Asterand Bioscience, una prestigiosa società impegnata nell’offerta di campioni di tessuto umano d’alta qualità e ben caratterizzati e di soluzioni per la ricerca basata su tessuto umano a sostegno della scoperta e dello sviluppo di farmaci, ha annunciato in data odierna di aver instaurato una collaborazione con MolecularMD per abbinare le competenze di MolecularMD quale fornitore di prodotti e servizi di diagnostica molecolare alle capacità di convalida di target di farmaci e candidati di Asterand Bio.


PORTLAND, Ore. & CAMBRIDGE, Mass. & DETROIT--(BUSINESS WIRE)--Asterand Bioscience, leider in kwalitatief hoogwaardig en goed gekarakteriseerd menselijk weefsel en daarop gebaseerde systemen ter ondersteuning van medicijnonderzoek, heeft vandaag zijn samenwerking met MolecularMD aangekondigd. Hiermee combineren ze de expertise van MolecularMD in moleculaire diagnostiek met Asterand Bio’s capaciteiten op vlak van medicijntargeting en validatie van kandidaat-medicijnen. MolecularMD is een bedrijf in moleculaire diagnostiek dat op maat gemaakte klinische tests en andere diagnostische hulpmiddelen ontwikkelt. Het ondersteunt klinisch-wetenschappelijk onderzoek en de vermarkting van doelgerichte therapieën tegen kanker. Door samen te werken creëren de bedrijven een workflow van begin tot eind voor de biofarmacie en versterken ze hun aanbod in testontwikkeling en validatie. Tegelijkertijd scheppen ze een mondiaal werkterrein voor de efficiënte uitvoering van hun analyses. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.

Loading MolecularMD collaborators
Loading MolecularMD collaborators